Skip to content

2019 Winners

The 2019 winners are:

Best ADC Platform Technology
Zymeworks (ZymeLink)
– Winner
LegoChem Bio (Scaffold Based Approach) – Runner Up


Best New Drug Developer

ADC Therapeutics
– Winner
Zymeworks – Runner Up

Most Promising Clinical Candidate
Trastuzumab Deruxtecan (DS-8201a)
– Winner
Enfortumab Vedotin (Seattle Genetics/Astellas) – Runner Up

Best Contract Manufacturing (CMO) Provider
BSP Pharmaceuticals
– Winner
Millipore Sigma
– Runner Up

Best Contract Research (CRO) Provider
PPD
– Winner
Abzena
– Runner Up

Best Pre-Clinical Publication

Winner:
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS. Nat Commun. 2018 May 4;9(1):1484.

Runner Up:
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S, Dal Corso A, Widmayer F, Neri D. J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.

Best Clinical Publication

Winner:
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.


Individual Input to the Field 2018

Dario Neri  (ETH Zurich)

Long Standing Contribution to the Field
Alain Beck (Pierre Fabre)